Short-term effects of the TNFα antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 3, 2007, Pages 337-342

  Arvidson, N G ^a,c   Larsen, A ^a   Aaseth, J ^a   Larsson, A ^b  

^a Kongsvinger Hospital   (Norway)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

Author keywords

Acute phase reaction; CRP; ESR; Fibrinogen; HAQ; Infliximab; RA; TNF

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DISEASE ACTIVITY; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GRANULOCYTE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ACTIVITIES OF DAILY LIVING; ACUTE-PHASE REACTION; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; HUMANS; MALE; METHOTREXATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247366405     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510601075903     Document Type: Article

References (21)

1. Charles P, Elliot MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
2. Richardson C, Emery P. Laboratory markers of disease activity. J Rheumatol 1996;Suppl 44:23-30.
3. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24:1477-85.
4. Ward MM. Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. J Rheumatol 2004;31:884-95.
5. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MHB, Birbara CA. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 2003;48:35-45.
6. Arvidson NG, Larsson A, Larsen A. Disease activity in rheumatoid arthritis: fibrinogen is superior to the erythrocyte sedimentation rate. Scand J Clin Lab Invest 2002;62:315-20.
7. Pollmacher T, Haack M, Schuld A, Reichenberg A, Yirmiya R. Low levels of circulating cytokines - Do they affect human brain functions? Brain Behav Immun 2002;16:525-32.
8. Zamarrón C, Maceiras F, Mera A, Gómez-Reino JJ. Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis 2004;63:88-90.
9. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patients' outcome in arthritis. Arthritis Rheum 1980;23:137-45.
10. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
11. Larsen A. How to apply Larsen score in evaluating radiographics of rheumatoid arthritis in long-term studies. J Rheumatol 1995;22:1974-5.
12. Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, et al. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology 2006;45:761-4.
13. Klimiuk PA, Sierakowsky S, Domyslawska I, Fiedorczyk M, Chwiecko J. Reduction of soluble adhesion molecyles (sICAM-1, sVCAM-1 and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp 2004;52:36-42.
14. Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol 2002;31:251-9.
15. Matteson EL. Extra-articular features of rheumatoid arthritis and systemic involvement. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Edinburgh: Mosby; 2003. pp 781-92.
16. Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S. Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996;39:1818-25.
17. Jacobs JWG, Geenen R, Evers AWM, van Jaarsveld CHM, Kraaimaat FW, Bijlsma JWJ. Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis. Ann Rheum Dis 2001;60:61-4.
18. Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White Jo, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis. Arthritis Rheum 2005;52:42-8.
19. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham study. J Am Med Assoc 1987;258:1183-6.
20. Sjöblom KG, Saxne T, Pettersson H, Wollheim FA. Factors related to the progression of joint destruction in rheumatoid arthritis. Scand J Rheumatol 1984;13:21-7.
21. Scott DL, Strand V. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical studies database. Rheumatology 2002;41:899-909.